WO2007095638A3 - Petites molecules contenant du bore en tant qu'agents anti-inflammatoires - Google Patents

Petites molecules contenant du bore en tant qu'agents anti-inflammatoires Download PDF

Info

Publication number
WO2007095638A3
WO2007095638A3 PCT/US2007/062350 US2007062350W WO2007095638A3 WO 2007095638 A3 WO2007095638 A3 WO 2007095638A3 US 2007062350 W US2007062350 W US 2007062350W WO 2007095638 A3 WO2007095638 A3 WO 2007095638A3
Authority
WO
WIPO (PCT)
Prior art keywords
boron
small molecules
containing small
inflammatory agents
disclosed
Prior art date
Application number
PCT/US2007/062350
Other languages
English (en)
Other versions
WO2007095638A2 (fr
Inventor
Stephen J Baker
Virginia Sanders
Tsutomu Akama
Carolyn Bellinger-Kawahara
Yvonne Freund
Kirk R Maples
Jacob J Plattner
Yong-Kang Zhang
Huchen Zhou
Vincent S Hernandez
Original Assignee
Anacor Pharmaceuticals Inc
Stephen J Baker
Virginia Sanders
Tsutomu Akama
Carolyn Bellinger-Kawahara
Yvonne Freund
Kirk R Maples
Jacob J Plattner
Yong-Kang Zhang
Huchen Zhou
Vincent S Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38372267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007095638(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0708051-4A priority Critical patent/BRPI0708051A2/pt
Priority to ES07757149.5T priority patent/ES2542342T3/es
Priority to KR1020147013817A priority patent/KR20140082842A/ko
Priority to NZ570257A priority patent/NZ570257A/en
Priority to MX2008010381A priority patent/MX2008010381A/es
Priority to RS20150474A priority patent/RS54108B1/en
Priority to EP07757149.5A priority patent/EP1988779B1/fr
Priority to KR1020177001541A priority patent/KR101819869B1/ko
Priority to EP13179945.4A priority patent/EP2719388B1/fr
Priority to KR1020137025594A priority patent/KR20130120552A/ko
Priority to KR1020147035518A priority patent/KR101622870B1/ko
Priority to AU2007214421A priority patent/AU2007214421B2/en
Priority to PL07757149T priority patent/PL1988779T3/pl
Priority to MX2013015092A priority patent/MX360301B/es
Priority to KR1020157027015A priority patent/KR20150113219A/ko
Application filed by Anacor Pharmaceuticals Inc, Stephen J Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R Maples, Jacob J Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S Hernandez filed Critical Anacor Pharmaceuticals Inc
Priority to RU2008137086/15A priority patent/RU2508113C2/ru
Priority to KR1020157000589A priority patent/KR20150013941A/ko
Priority to MEP-2015-97A priority patent/ME02188B/me
Priority to CN2007800133393A priority patent/CN101420854B/zh
Priority to JP2008555528A priority patent/JP5419466B2/ja
Priority to SI200731663T priority patent/SI1988779T1/sl
Priority to DK07757149.5T priority patent/DK1988779T5/en
Priority to PL13179945T priority patent/PL2719388T3/pl
Priority to CA2642583A priority patent/CA2642583C/fr
Publication of WO2007095638A2 publication Critical patent/WO2007095638A2/fr
Publication of WO2007095638A3 publication Critical patent/WO2007095638A3/fr
Priority to IL193230A priority patent/IL193230A/en
Priority to ZA2008/06754A priority patent/ZA200806754B/en
Priority to HK09101607.4A priority patent/HK1121344A1/xx
Priority to HRP20150710TT priority patent/HRP20150710T1/hr
Priority to IL241792A priority patent/IL241792B/en
Priority to CY20191100519T priority patent/CY1121899T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne des procédés destinés à traiter des états anti-inflammatoires à l'aide de petites molécules contenant du bore.
PCT/US2007/062350 2006-02-16 2007-02-16 Petites molecules contenant du bore en tant qu'agents anti-inflammatoires WO2007095638A2 (fr)

Priority Applications (30)

Application Number Priority Date Filing Date Title
CA2642583A CA2642583C (fr) 2006-02-16 2007-02-16 Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
KR1020157000589A KR20150013941A (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
KR1020147013817A KR20140082842A (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
RU2008137086/15A RU2508113C2 (ru) 2006-02-16 2007-02-16 Борсодержащие малые молекулы в качестве противовоспалительных средств
MX2008010381A MX2008010381A (es) 2006-02-16 2007-02-16 Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
RS20150474A RS54108B1 (en) 2006-02-16 2007-02-16 SMALL MOLECULES CONTAINING BORON AS AGENTS FOR INFLAMMATION
EP07757149.5A EP1988779B1 (fr) 2006-02-16 2007-02-16 Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
ES07757149.5T ES2542342T3 (es) 2006-02-16 2007-02-16 Pequeñas moléculas que contienen boro como agentes antiinflamatorios
EP13179945.4A EP2719388B1 (fr) 2006-02-16 2007-02-16 Petites molécules contenant du bore en tant qu'agents anti-inflammatoires
KR1020137025594A KR20130120552A (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
KR1020147035518A KR101622870B1 (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
AU2007214421A AU2007214421B2 (en) 2006-02-16 2007-02-16 Boron-containing small molecules as anti-inflammatory agents
PL07757149T PL1988779T3 (pl) 2006-02-16 2007-02-16 Małe cząsteczki zawierające bor jako środki przeciwzapalne
MEP-2015-97A ME02188B (me) 2006-02-16 2007-02-16 Mali molekuli koji sadrže boron kao antiinflamatorni agensi
KR1020157027015A KR20150113219A (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
BRPI0708051-4A BRPI0708051A2 (pt) 2006-02-16 2007-02-16 moléculas pequenas contendo boro como agentes antiflamatórios
NZ570257A NZ570257A (en) 2006-02-16 2007-02-16 Boron-containing small molecules as anti-inflammatory agents
KR1020177001541A KR101819869B1 (ko) 2006-02-16 2007-02-16 항염증제로서 보론함유 소분자
MX2013015092A MX360301B (es) 2006-02-16 2007-02-16 Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
CN2007800133393A CN101420854B (zh) 2006-02-16 2007-02-16 作为抗炎药的含硼的小分子
JP2008555528A JP5419466B2 (ja) 2006-02-16 2007-02-16 抗炎症剤としてのホウ素含有小分子
SI200731663T SI1988779T1 (sl) 2006-02-16 2007-02-16 Bor-vsebujoče majhne molekule kot protivnetna sredstva
DK07757149.5T DK1988779T5 (en) 2006-02-16 2007-02-16 SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
PL13179945T PL2719388T3 (pl) 2006-02-16 2007-02-16 Małe cząsteczki zawierające bor jako środki przeciwzapalne
ZA2008/06754A ZA200806754B (en) 2006-02-16 2008-08-04 Boron-containing small molecules as anti-inflammatory agents
IL193230A IL193230A (en) 2006-02-16 2008-08-04 Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
HK09101607.4A HK1121344A1 (en) 2006-02-16 2009-02-19 Boron-containing small molecules as anti-inflammatory agents
HRP20150710TT HRP20150710T1 (hr) 2006-02-16 2015-07-01 Male molekule koje sadrže bor kao protu-upalni agensi
IL241792A IL241792B (en) 2006-02-16 2015-09-21 Boron-containing molecules with anti-inflammatory ingredients
CY20191100519T CY1121899T1 (el) 2006-02-16 2019-05-14 Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77453206P 2006-02-16 2006-02-16
US60/774,532 2006-02-16
US82388806P 2006-08-29 2006-08-29
US60/823,888 2006-08-29

Publications (2)

Publication Number Publication Date
WO2007095638A2 WO2007095638A2 (fr) 2007-08-23
WO2007095638A3 true WO2007095638A3 (fr) 2008-07-31

Family

ID=38372267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/062350 WO2007095638A2 (fr) 2006-02-16 2007-02-16 Petites molecules contenant du bore en tant qu'agents anti-inflammatoires

Country Status (25)

Country Link
US (11) US8168614B2 (fr)
EP (2) EP2719388B1 (fr)
JP (4) JP5419466B2 (fr)
KR (7) KR101622870B1 (fr)
CN (2) CN101420854B (fr)
AU (1) AU2007214421B2 (fr)
BR (1) BRPI0708051A2 (fr)
CA (2) CA2642583C (fr)
CY (1) CY1121899T1 (fr)
DK (2) DK1988779T5 (fr)
ES (2) ES2542342T3 (fr)
HK (1) HK1121344A1 (fr)
HR (1) HRP20150710T1 (fr)
HU (2) HUE044941T2 (fr)
IL (2) IL193230A (fr)
ME (1) ME02188B (fr)
MX (2) MX360301B (fr)
NZ (1) NZ570257A (fr)
PL (2) PL1988779T3 (fr)
PT (2) PT2719388T (fr)
RS (1) RS54108B1 (fr)
RU (2) RU2642628C2 (fr)
SI (2) SI2719388T1 (fr)
WO (1) WO2007095638A2 (fr)
ZA (1) ZA200806754B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2343304T1 (sl) * 2005-02-16 2015-08-31 Anacor Pharmaceuticals, Inc. Biocidne boroftalidne spojine
EP1976536A4 (fr) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc Petites molecules contenant du bore
CN101420854B (zh) 2006-02-16 2013-08-07 安纳考尔医药公司 作为抗炎药的含硼的小分子
WO2007131072A2 (fr) 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Substances thérapeutiques contenant du bore résistant à l'hydrolyse et méthodes d'utilisation
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
JP2015178508A (ja) * 2008-01-09 2015-10-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
JP5745279B2 (ja) * 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ，インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
RU2015109165A (ru) 2008-03-06 2015-11-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
EP2187893A4 (fr) * 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2009140309A2 (fr) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
EP2348863A4 (fr) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045505A1 (fr) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Petites molécules contenant du bore en tant qu’agents antiprotozoaires
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
US8461364B2 (en) 2008-12-17 2013-06-11 Glaxosmithkline Llc Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
CA2757622A1 (fr) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibiteurs d'hydrolase d'amide d'acide gras
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
WO2011019616A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore à titre d'agents anti-protozoaires
WO2011019612A1 (fr) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents antiprotozoaires
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
CA2774373A1 (fr) * 2009-09-17 2011-03-24 Vanderbilt University Analogues d'heteroarylamide substitue en tant que modulateurs allosteriques negatifs de mglur5, et leurs procedes de preparation et d'utilisation
WO2011037731A1 (fr) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011063293A1 (fr) 2009-11-20 2011-05-26 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore en tant qu'agents antihelminthes
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore
CN102834401B (zh) 2010-02-03 2016-08-24 无限药品股份有限公司 脂肪酸酰胺水解酶抑制剂
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
JP5699030B2 (ja) * 2010-07-05 2015-04-08 Ａｘｉｓ株式会社 エタネルセプトを含む線維筋痛症の治療剤
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
EP2611427B1 (fr) 2010-09-01 2018-10-17 Arena Pharmaceuticals, Inc. Formes galéniques à libération modifiée d'agonistes de 5-ht2c, utiles pour la gestion du poids
SG10201507032YA (en) 2010-09-07 2015-10-29 Anacor Pharmaceuticals Inc Benzoxaborole derivatives for treating bacterial infections
KR101849813B1 (ko) 2010-12-15 2018-04-17 오라텍 세라퓨틱스 엘엘씨 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
WO2013033461A1 (fr) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Dérivés d'ester d'acide boronique hétérocyclique et leurs utilisations thérapeutiques
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
WO2013093615A1 (fr) * 2011-12-22 2013-06-27 Micurx Pharmaceuticals, Inc. Composés de bore tricycliques pour une thérapie antimicrobienne
CN104185621B (zh) 2012-02-27 2016-09-07 欧拉泰克工业有限责任公司 用于制备3-甲磺酰基丙腈的方法
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2875053C (fr) 2012-06-05 2020-07-14 Olatec Industries Llc Composition pharmaceutique pour traiter l'inflammation et la douleur
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN104349772B (zh) 2012-06-11 2017-09-05 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的化合物
US9114122B2 (en) 2012-06-14 2015-08-25 Olatec Industries Llc Compounds for treating inflammation and pain
US8980544B2 (en) 2012-11-27 2015-03-17 The Penn State Research Foundation Boronic and borinic acid compounds as inhibitors of sulfenic acid-containing proteins
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EA201591004A1 (ru) 2013-01-04 2016-02-29 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
AR094666A1 (es) 2013-01-30 2015-08-19 Dow Agrosciences Llc Uso de benzoxaborolas como agentes antimicrobianos volátiles en carnes, plantas o partes de plantas
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2014121124A1 (fr) 2013-02-01 2014-08-07 Anacor Pharmaceuticals, Inc. Molécules de petite taille contenant du bore en qualité d'agents anti-protozoaires
KR101636431B1 (ko) * 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
WO2015042532A1 (fr) * 2013-09-23 2015-03-26 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
US9585958B2 (en) * 2013-09-24 2017-03-07 The Regents Of The University Of California Compositions and methods for reducing lactate levels
WO2015077246A1 (fr) 2013-11-19 2015-05-28 Vanderbilt University Composés imidazopyridine et triazolopyridine substitués utilisés comme modulateurs allostériques négatifs de mglur
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
LT3140310T (lt) 2014-05-05 2019-11-25 Rempex Pharmaceuticals Inc Boronato druskų sintezė ir jų panaudojimas
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
EP3164406A4 (fr) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
KR20170024068A (ko) 2014-07-01 2017-03-06 다이이찌 산쿄 가부시키가이샤 항박테리아제로서의 삼환식 벤즈옥사보롤
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
CN107105666A (zh) * 2015-01-13 2017-08-29 先正达参股股份有限公司 新颖的杀微生物剂
WO2016149393A1 (fr) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Dérivés d'acide boronique et leurs utilisations thérapeutiques
EP3280262B1 (fr) 2015-04-09 2022-07-06 The Penn State Research Foundation Composition antifongicide contenant du benzoxaborole
CA3014757C (fr) * 2015-08-06 2020-01-14 The Penn State Research Foundation Revetement contenant du benzoxaborole resistant a un champignon susceptible d'etre porte par la cellulose
IL259693B (en) * 2015-11-30 2022-07-01 Anacor Pharmaceuticals Inc Preparations for topical administration and their use for the treatment of inflammation
WO2017151489A1 (fr) 2016-03-02 2017-09-08 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
CN113845536A (zh) 2016-03-02 2021-12-28 比尔及梅琳达盖茨基金会 含硼小分子
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
RS64770B1 (sr) 2016-03-07 2023-11-30 Agrofresh Inc Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve
MX2018013742A (es) * 2016-05-09 2019-08-01 Anacor Pharmaceuticals Inc Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CA3026316A1 (fr) 2016-06-03 2017-12-07 Basf Se Composes benzoxarobole
DK3478693T3 (da) 2016-06-30 2021-09-20 Qpex Biopharma Inc Boronsyrederivater og terapeutiske anvendelser deraf
CN107759625B (zh) * 2016-08-22 2020-12-29 药源药物化学（上海）有限公司 4-(1-羟基-1,3-二氢苯并[c][1,2]氧杂硼杂环戊二烯-5-基氧基)苯氰的制备方法
WO2019190503A1 (fr) * 2018-03-28 2019-10-03 Cove Bio Llc Procédés et compositions pour le traitement de la maladie de parkinson
GB201701583D0 (en) 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
WO2018150327A1 (fr) * 2017-02-14 2018-08-23 Wavelength Enterprises Ltd Procédé de production de crisaborole
US10961261B2 (en) 2017-03-01 2021-03-30 Anacor Pharmaceuticals, Inc. Oxaborole analogs and uses thereof
EP3576747A4 (fr) * 2017-03-09 2020-12-16 The Penn State Research Foundation Petites molécules contenant du bore pour inhiber l'activité d'une protéine tyrosine phosphatase de type récepteur
US10981939B2 (en) 2017-05-12 2021-04-20 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole)
CN108864160A (zh) * 2017-05-16 2018-11-23 苏州旺山旺水生物医药有限公司 含硼小分子的制备方法
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその合成
CN109206446B (zh) * 2017-11-14 2021-08-03 深圳市塔吉瑞生物医药有限公司 一种取代的含硼的化合物及包含该化合物的药物组合物
US11834466B2 (en) 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
US10329311B1 (en) * 2017-12-21 2019-06-25 Olon S.P.A. Process for the preparation of crisaborole
ES2949908T3 (es) 2018-01-09 2023-10-03 Halcyon Labs Private Ltd Proceso para la preparación de Crisaborol y sus intermedios
US11427603B2 (en) 2018-03-09 2022-08-30 University Of The Sciences Protective groups and methods for protecting benzoxaboroles or oxaboroles
EP3542788A1 (fr) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Composition topique comprenant calcipotriol et dipropionate de bétaméthasone
CN108997394A (zh) * 2018-06-12 2018-12-14 广州百霆医药科技有限公司 苯并氧杂硼杂环戊烷类化合物及其制备方法
CN108659024A (zh) * 2018-07-24 2018-10-16 武汉轻工大学 克立硼罗的制备方法
EP3829538A1 (fr) * 2018-07-31 2021-06-09 MC2 Therapeutics Limited Composition topique
CN112867494A (zh) 2018-08-18 2021-05-28 博瑞金股份有限公司 取代苯并氧杂硼杂环戊烯的固体形式和其组合物
KR102007887B1 (ko) 2018-10-25 2019-08-07 (주)씨플렉스필름 회전기능을 갖는 수중 촬영장치
KR102038146B1 (ko) 2018-10-25 2019-11-04 김준희 밸런스 웨이트 위치 이동형 크레인을 포함하는 수중 촬영 시스템
CN109456347B (zh) * 2018-10-29 2021-02-05 安徽省庆云医药股份有限公司 一种克立硼罗的制备方法
CN112174989B (zh) 2019-07-02 2023-06-20 江西同和药业股份有限公司 一种克立硼罗的制备方法
CN110664756B (zh) * 2019-10-09 2020-11-17 吉林大学 一种小儿外伤喷雾剂及其制备方法
CN111303195B (zh) * 2020-04-07 2022-09-27 中国医学科学院放射医学研究所 一类含硼小分子化合物、其制备方法及应用
EP4204012A1 (fr) 2020-08-31 2023-07-05 Pfizer Inc. Procédés de protection de l'arn
US11766369B1 (en) 2020-09-30 2023-09-26 Douglas Dillon Single use protective cover for patient transport device
CN114685537A (zh) * 2020-12-28 2022-07-01 南京理工大学 丁苯酞衍生物g-3702在制备脑缺血再灌注损伤预防和治疗药物中的应用
CN113136023B (zh) * 2021-04-25 2021-11-30 盐城海关综合技术服务中心 含羟甲基多孔芳香骨架的制备方法及其功能化材料和应用
WO2023076453A1 (fr) * 2021-10-29 2023-05-04 An2 Therapeutics, Inc. Traitement d'états neuroinflammatoires
WO2023244775A1 (fr) * 2022-06-17 2023-12-21 Boehringer Ingelheim Animal Health USA Inc. Composés pyrimidine contenant du bore, compositions comprenant ceux-ci, méthodes et utilisations associées

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688928A (en) * 1994-01-28 1997-11-18 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
US5880188A (en) * 1994-06-09 1999-03-09 Zeneca Limited Oxaboroles and salts thereof, and their use as biocides
US5962498A (en) * 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US20030032673A1 (en) * 2001-07-19 2003-02-13 Isis Innovation Limited Therapeutic strategies for prevention and treatment of alzheimer's disease
US20050239170A1 (en) * 2000-07-14 2005-10-27 Hedley Mary L Alpha-MSH related compounds and methods of use
US20060009386A1 (en) * 2004-05-12 2006-01-12 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
GB1396904A (en) 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9500856D0 (en) 1995-01-17 1995-03-08 Zeneca Ltd Composition and use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
AU3102697A (en) 1996-06-19 1998-01-07 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
AU4486097A (en) 1996-09-19 1998-04-14 Board Of Trustees Of The Leland Stanford Junior University Dna adenine methyltransferases and uses thereof
WO1998024753A1 (fr) 1996-12-02 1998-06-11 Chisso Corporation Derives de nitro-alcool actifs optiquement, derives d'amino-alcool actifs optiquement et leur procede de preparation
US6221640B1 (en) 1997-05-14 2001-04-24 Cubist Pharmaceuticals, Inc. Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
AU762992B2 (en) 1998-11-06 2003-07-10 Abbott Gmbh & Co. Kg Tricyclic pyrazole derivatives
US6462036B1 (en) * 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000044387A1 (fr) 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
CN1370170A (zh) 1999-05-25 2002-09-18 宾夕法尼亚州研究基金会 Dna甲基转移酶抑制剂
RU2247719C2 (ru) * 1999-07-16 2005-03-10 Лео Фармасьютикал Продактс Лтд.А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) Аминобензофеноны как ингибиторы il-1 бета и tnf-альфа, фармацевтическая композиция и способ лечения и/или профилактики воспалительных заболеваний
EP1210449B1 (fr) 1999-08-25 2006-12-27 Ambergen, Inc. Techniques de detection, d'analyse et d'isolation de nouvelles proteines
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
WO2001049302A1 (fr) 2000-01-06 2001-07-12 Marantech Holding, Llc Compositions et procedes destines a faciliter la croissance de la peau et a gerer des affections cutanees
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
JP2004524281A (ja) 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
WO2003033002A1 (fr) * 2001-10-11 2003-04-24 Ono Pharmaceutical Co Inhibiteurs de l'augmentation de la concentration du calcium intracellulaire
CA2473238A1 (fr) 2002-01-10 2003-07-24 The Penn State Research Foundation Procedes de preparation d'alkyl diarylborinates et d'acides diarylboroniques complexes
MX249034B (es) * 2002-05-28 2007-09-14 Dimensional Pharm Inc Amidinas de tiofeno novedosas, composiciones de las mismas, y metodos para tratar enfermedades y condiciones mediadas por el complemento.
IL166156A0 (en) 2002-07-09 2006-01-15 Point Therapeutics Inc Boroproline compound combination therapy
DE60313357T2 (de) 2002-12-02 2008-01-03 Solvias Ag Verfahren zur katalytischen hydrierung von kohlenstoff-heteroatom-doppelbindungen
EP1581500A4 (fr) 2002-12-18 2008-03-05 Anacor Pharmaceuticals Inc Antibiotiques contenant des complexes d'acide borinique et leurs procedes d'utilisation
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
WO2005000200A2 (fr) 2003-05-09 2005-01-06 Sugen, Inc. Nouvelles kinases
EP1638578A4 (fr) 2003-06-16 2009-04-01 Anacor Pharmaceuticals Inc Agents therapeutiques contenant du bore et a resistance hydrolytique et procedes pour les utiliser
EP1765360B1 (fr) 2004-06-14 2009-11-11 Anacor Pharmaceuticals, Inc. Utilisations antivirales de complexes d'acide borinique
AR049915A1 (es) 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062731A1 (fr) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Utilisation de la phenanthroline et de ses derives pour abaisser la tension intraoculaire d'un oeil affecte
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
SI2343304T1 (sl) 2005-02-16 2015-08-31 Anacor Pharmaceuticals, Inc. Biocidne boroftalidne spojine
WO2006096131A1 (fr) 2005-03-08 2006-09-14 Agency For Science, Technology And Research Catalyseurs chiraux a base de bisoxazoline
AR054336A1 (es) 2005-03-30 2007-06-20 Astion Dev As Tratamiento de enfermedades dermatologicas y del prurito
WO2007022437A2 (fr) 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Nouveaux agents thérapeutiques pour le traitement de cancers, de maladies métaboliques et de troubles cutanés
EP1976536A4 (fr) 2005-12-30 2011-03-02 Anacor Pharmaceuticals Inc Petites molecules contenant du bore
CN101420854B (zh) 2006-02-16 2013-08-07 安纳考尔医药公司 作为抗炎药的含硼的小分子
CA2654449A1 (fr) * 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Composes destines au traitement d'une maladie periodontale
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
RU2015109165A (ru) 2008-03-06 2015-11-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
EP2187893A4 (fr) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2009140309A2 (fr) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
EP2348863A4 (fr) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Petites molécules contenant du bore
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (fr) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Petites molécules contenant du bore en tant qu’agents antiprotozoaires
US8461364B2 (en) 2008-12-17 2013-06-11 Glaxosmithkline Llc Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
RU2012107163A (ru) 2009-07-28 2013-09-10 Анакор Фармасьютикалз, Инк. Тризамещенные борсодержащие молекулы
US8461134B2 (en) 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962498A (en) * 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US5688928A (en) * 1994-01-28 1997-11-18 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
US5880188A (en) * 1994-06-09 1999-03-09 Zeneca Limited Oxaboroles and salts thereof, and their use as biocides
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US20050239170A1 (en) * 2000-07-14 2005-10-27 Hedley Mary L Alpha-MSH related compounds and methods of use
US20030032673A1 (en) * 2001-07-19 2003-02-13 Isis Innovation Limited Therapeutic strategies for prevention and treatment of alzheimer's disease
US20060009386A1 (en) * 2004-05-12 2006-01-12 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957049B2 (en) 2008-04-09 2015-02-17 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase

Also Published As

Publication number Publication date
IL193230A0 (en) 2009-08-03
US8501712B2 (en) 2013-08-06
US20200046745A1 (en) 2020-02-13
KR20170012570A (ko) 2017-02-02
KR20130120552A (ko) 2013-11-04
PT1988779E (pt) 2015-09-04
US20120264714A1 (en) 2012-10-18
MX2008010381A (es) 2009-03-05
KR101622870B1 (ko) 2016-05-19
KR20080110751A (ko) 2008-12-19
US20230008130A1 (en) 2023-01-12
US20150216885A1 (en) 2015-08-06
DK1988779T5 (en) 2016-10-10
JP2016190865A (ja) 2016-11-10
HK1121344A1 (en) 2009-04-24
IL193230A (en) 2015-10-29
KR20150113219A (ko) 2015-10-07
HUE025048T2 (en) 2016-01-28
WO2007095638A2 (fr) 2007-08-23
CN101420854B (zh) 2013-08-07
JP2013253097A (ja) 2013-12-19
RS54108B1 (en) 2015-12-31
KR20150004937A (ko) 2015-01-13
CN103479654B (zh) 2018-02-09
EP1988779A2 (fr) 2008-11-12
SI2719388T1 (sl) 2019-06-28
CA2933994A1 (fr) 2007-08-23
US20190160081A1 (en) 2019-05-30
JP2009531292A (ja) 2009-09-03
US20170258819A1 (en) 2017-09-14
KR20150013941A (ko) 2015-02-05
US20200179418A1 (en) 2020-06-11
US9682092B2 (en) 2017-06-20
US9029353B2 (en) 2015-05-12
US20210000847A1 (en) 2021-01-07
CA2642583C (fr) 2016-08-23
AU2007214421B2 (en) 2012-11-29
HUE044941T2 (hu) 2019-11-28
EP1988779A4 (fr) 2010-12-22
DK2719388T3 (da) 2019-05-13
ES2728455T3 (es) 2019-10-24
JP2015147795A (ja) 2015-08-20
MX360301B (es) 2018-10-29
JP5419466B2 (ja) 2014-02-19
IL241792B (en) 2019-08-29
US20190282594A1 (en) 2019-09-19
EP1988779B1 (fr) 2015-06-24
CY1121899T1 (el) 2020-10-14
ME02188B (me) 2016-02-20
PL2719388T3 (pl) 2019-11-29
AU2007214421A1 (en) 2007-08-23
EP2719388A1 (fr) 2014-04-16
RU2642628C2 (ru) 2018-01-25
HRP20150710T1 (hr) 2015-08-14
PL1988779T3 (pl) 2015-10-30
PT2719388T (pt) 2019-06-11
KR101819869B1 (ko) 2018-01-17
KR20140082842A (ko) 2014-07-02
RU2508113C2 (ru) 2014-02-27
US20130316979A1 (en) 2013-11-28
CN101420854A (zh) 2009-04-29
CN103479654A (zh) 2014-01-01
US8168614B2 (en) 2012-05-01
ZA200806754B (en) 2014-05-28
RU2008137086A (ru) 2010-03-27
BRPI0708051A2 (pt) 2011-05-17
IL241792A0 (en) 2015-11-30
JP6266708B2 (ja) 2018-01-24
ES2542342T3 (es) 2015-08-04
DK1988779T3 (en) 2015-07-13
SI1988779T1 (sl) 2015-08-31
RU2013152132A (ru) 2015-05-27
US20070293457A1 (en) 2007-12-20
EP2719388B1 (fr) 2019-04-10
CA2642583A1 (fr) 2007-08-23
NZ570257A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2009111676A3 (fr) Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2007115821A3 (fr) Composés organiques
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
WO2008067219A3 (fr) Modulateurs quinazolinones de tgr5
WO2007081751A9 (fr) Compositions et procedes destines au traitement du cancer
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
WO2009015037A3 (fr) Indazoles substitués par du 5-pyridinone
WO2007122382A3 (fr) Lycopène pour le traitement d'une dysmétabolie
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
WO2008002855A8 (fr) Procédés de traitement des blessures
TNSN08496A1 (en) Aminothiazoles and their uses
WO2008085927A3 (fr) Procédés, compositions et kits destinés au traitement de la douleur
IL226362A0 (en) compounds, and methods for treating cancer
TN2009000495A1 (en) Macrocycles and their uses
WO2008063957A3 (fr) Méthodes de traitement de troubles induits par des endotoxines
WO2008009895A3 (fr) Matriptase-2
UA37933U (ru) Применение амкесола как вещества с противовоспалительными свойствами
AU2006903728A0 (en) Method for the treatment of cancer
AU2006906276A0 (en) Compositions and methods for the treatment of prostate cancer
WO2008006099A3 (fr) Traitement de troubles psychiatriques
AU2007901333A0 (en) Method for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007757149

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1645/MUMNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 193230

Country of ref document: IL

Ref document number: 570257

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007214421

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/010381

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008555528

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2642583

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008137086

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780013339.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: PI0708051

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080818

WWE Wipo information: entry into national phase

Ref document number: 1020147013817

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020147035518

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020157000589

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P-2015/0474

Country of ref document: RS

WWE Wipo information: entry into national phase

Ref document number: 241792

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020157027015

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1020177001541

Country of ref document: KR